KYOTO, Japan, June 26, 2026
Nippon Shinyaku Co., Ltd. announced it has entered into an option agreement with Elixirgen Therapeutics, Inc. that could grant the company exclusive worldwide rights to develop and commercialize EXG-7001, an investigational mRNA-based therapy for Duchenne muscular dystrophy (DMD). Under the agreement, if Nippon Shinyaku exercises the option and the therapy receives regulatory approval in the United States, its wholly owned U.S. subsidiary, NS Pharma, Inc., will commercialize EXG-7001. The partnership strengthens Nippon Shinyaku’s strategy of expanding its rare disease pipeline through innovative genetic medicine technologies.
Collaboration Targets Next-Generation DMD Treatment
The agreement brings together Nippon Shinyaku’s expertise in rare disease drug development and Elixirgen Therapeutics’ mRNA platform to accelerate the advancement of EXG-7001. The companies aim to develop a therapy capable of addressing Duchenne muscular dystrophy, a progressive genetic disorder caused by the absence of functional dystrophin protein, which results in severe muscle weakness affecting skeletal, cardiac, and respiratory muscles. By securing an option for global development and commercialization, Nippon Shinyaku is positioning itself to expand treatment options for patients with this debilitating rare disease.
EXG-7001 Designed to Restore Full-Length Dystrophin
EXG-7001 is a locally administered mRNA-based therapeutic candidate designed to express full-length human dystrophin protein directly within muscle cells. Unlike mutation-specific therapies, EXG-7001 is intended to work regardless of the patient’s underlying genetic mutation, making it a potentially broader treatment approach for individuals living with Duchenne muscular dystrophy. The investigational therapy aims to suppress local muscle dysfunction by restoring dystrophin expression, while Elixirgen Therapeutics continues preparations to begin clinical trials in the United States.
Advertisement
Companies Advance Rare Disease Innovation
The collaboration reflects Nippon Shinyaku’s long-term commitment to developing innovative therapies for rare and intractable diseases through strategic partnerships. If successfully developed and approved, EXG-7001 could become an important addition to the company’s neuromuscular disease portfolio through commercialization by NS Pharma in the United States. Meanwhile, Elixirgen Therapeutics continues to advance its proprietary technologies focused on developing therapies for rare genetic and aging-associated diseases, supporting the broader goal of delivering next-generation treatments to patients with significant unmet medical needs.
Source: Nippon Shinyaku press release
